Editas director granted 51,700 stock options
Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Editas Medicine director Andrew Hirsch received a stock option grant as part of his compensation. The award covers 51,700 options to buy Editas Medicine common stock at an exercise price of $2.55 per share. The option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027, with an expiration date of June 16, 2036. Following this grant, Hirsch holds 51,700 stock options directly, and there were no open‑market stock purchases or sales reported in this filing.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 51,700 | $0.00 | $0.00 |
Footnotes (1)
- F1. This option was granted on June 17, 2026 and is scheduled to vest in full on June 17, 2027.
Key Figures
Key Terms
Stock Option (right to buy) financial
Grant, award, or other acquisition financial
Common Stock financial
vest in full financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Andrew Hirsch report in this Form 4 for Editas Medicine (EDIT)?
How many Editas Medicine (EDIT) stock options were granted to Andrew Hirsch?
What is the exercise price of Andrew Hirsch’s Editas Medicine (EDIT) stock options?
When do Andrew Hirsch’s Editas Medicine (EDIT) stock options vest and expire?
AI-generated analysis. How Rhea-AI works. Not financial advice.